Lampalizumab
Lampalizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against complement factor D.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
208 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 25 | 32 | 21 | 2 | 1 | 70 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 21 | 25 | 7 | 1 | 1 | 46 |
| Myeloid leukemia | D007951 | — | C92 | 21 | 23 | 7 | 1 | 1 | 44 |
| Myelodysplastic syndromes | D009190 | — | D46 | 13 | 13 | 1 | 1 | — | 23 |
| Syndrome | D013577 | — | — | 10 | 11 | 2 | 1 | 1 | 20 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 5 | 2 | — | 1 | — | 7 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 5 | 2 | — | 1 | — | 7 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 3 | 1 | 1 | — | 5 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | 1 | — | 1 | 3 | 5 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 3 | — | 1 | — | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 8 | 16 | 15 | — | — | 37 |
| Lymphoid leukemia | D007945 | — | C91 | 6 | 10 | 13 | — | — | 27 |
| Lymphoma | D008223 | — | C85.9 | 5 | 14 | 7 | — | — | 24 |
| Neoplasms | D009369 | — | C80 | 8 | 7 | 1 | — | 1 | 16 |
| Carcinoma | D002277 | — | C80.0 | 5 | 6 | 2 | — | — | 12 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 5 | 4 | — | — | 12 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 6 | 2 | 1 | — | — | 8 |
| Hodgkin disease | D006689 | — | C81 | 2 | 4 | 1 | — | — | 7 |
| Philadelphia chromosome | D010677 | — | — | 1 | 3 | 3 | — | — | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 4 | 2 | — | — | 7 |
Show 55 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 10 | 14 | — | — | — | 21 |
| Preleukemia | D011289 | — | — | 10 | 9 | — | — | — | 15 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 3 | — | — | — | 6 |
| Hematologic neoplasms | D019337 | — | — | 2 | 4 | — | — | — | 5 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 4 | — | — | — | 5 |
| Mantle-cell lymphoma | D020522 | — | — | 1 | 5 | — | — | — | 5 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 3 | 4 | — | — | — | 5 |
| T-cell lymphoma | D016399 | — | — | — | 5 | — | — | — | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 1 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 2 | — | — | — | 4 |
Show 87 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 2 | — | — | — | — | 2 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | — | — | — | — | 1 |
| Myeloid sarcoma | D023981 | — | C92.3 | 1 | — | — | — | — | 1 |
| Hiv | D006678 | — | — | 1 | — | — | — | — | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal diseases | D005767 | — | — | — | — | — | — | 2 | 2 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | — | — | — | 1 | 1 |
| Pouchitis | D019449 | EFO_0003921 | K91.850 | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | — | 1 | 1 |
| Chronic hepatitis | D006521 | — | K73.9 | — | — | — | — | 1 | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | — | 1 | 1 |
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lampalizumab |
| INN | lampalizumab |
| Description | Lampalizumab (humanized mab) |
| Classification | Antibody |
| Drug class | ionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]; monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109408 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | UWU93Y99R3 (ChemIDplus, GSRS) |
Target
Agency Approved
CFD
CFD
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 329 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use